Obesity-fighting drugs may reduce alcohol consumption in individuals with alcohol use disorder

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalizations among individuals with alcohol use disorder, AUD.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup